<sup>18</sup>F-FDG PET/CT与<sup>18</sup>F-FDG PET/MRI在卵巢癌临床应用中的进展

张伟; 于丽娟; 张伟; 于丽娟

doi:10.3760/cma.j.issn.1673-4114.2018.05.010

[1]

章伟玲. PET/CT在诊断卵巢良恶性及交界性肿瘤中的价值[J].医药论坛杂志, 2011, 32 (24):88-89.
Zhang WL.Value of PET/CT in diagnosis of benign or malignant and borderline ovarian tumors[J]. J Med Forum, 2011, 32 (24):88-89.

[2]

龚静, 刘陶, 王雅琴, 等. CEA及CA125检测与PET/CT显像在诊断卵巢癌中的价值[J].实用妇产科杂志, 2016, 32 (12):946-947.
Gong J, Liu T, Wang YQ, et al. The value of CEA and CA125 detection and PET/CT imaging in diagnosing ovarian cancer[J]. J Pract Obstet Gynecol, 2016, 32 (12):946-947.

[3]

Risum S, Høgdall C, Loft A, et al. The diagnostic value of PET/CT for primary ovarian cancer-a prospective study[J]. Gynecol Oncol, 2007, 105 (1):145-149. DOI:10.1016/j.ygyno.2006.11.022.

[4]

Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer:correlation between PET/CT, Doppler US, and CT or MRI[J]. Gynecol Oncol, 2010, 116 (3):389-394. DOI:10.1016/j.ygyno.2009.10.059.

[5]

Tanizaki Y, Kobayashi A, Shiro M, et al. Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer[J]. Int J Gynecol Cancer, 2014, 24 (3):454-460. DOI:10.1097/IGC.0000000000000074.

[6]

祝英杰, 杨宏英, 严志凌, 等. ¹⁸F-FDGPET/CT显像在卵巢肿瘤分期中的应用价值[J].昆明医科大学学报, 2014, 35 (4):79-82.
Zhu YJ, Yang HY, Yan ZL, et al. Clinical Application of (¹⁸F-FDG) PET/CT in Staging of Ovarian Carcinoma[J]. J Kunming Med Univ, 2014, 35 (4):79-82.

[7]

Dauwen H, Van Calster B, Deroose CM, et al. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer[J]. Gynecol Oncol, 2013, 131 (3):694-700. DOI:10.1016/j.ygyno.2013.08.020.

[8]

Yuan Y, Gu ZX, Tao XF, et al. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer:a meta-analysis[J]. Eur J Radiol, 2012, 81 (5):1002-1006. DOI:10.1016/j.ejrad.2011.01.112.

[9]

Rubini G, Altini C, Notaristefano A, et al. Role of ¹⁸F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125[J]. Rev Esp Med Nucl Imagen Mol, 2014, 33 (1):22-27. DOI:10.1016/j.remn.2013.06.008.

[10]

Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer[J]. J Clin Oncol, 2005, 23 (30):7445-7453. DOI:10.1200/JCO.2005.06.965.

[11]

Antunovic L, Cimitan M, Borsatti E, et al. Revisiting the clinical value of ¹⁸F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities[J/OL]. Clin Nucl Med, 2012, 37 (8): e184-188[2018-01-17]. https://insights.ovid.com/pubmed?pmid=22785525. DOI: 10.1097/RLU.0b013e31825b2583.

[12]

Lu KH, Skates S, Hernandez MA, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value[J]. Cancer, 2013, 119 (19):3454-3461. DOI:10.1002/cncr.28183.

[13]

Yang ZJ, Zhao BB, Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer[J]. J Ovarian Res, 2016, 9 (1):57. DOI:10.1186/s13048-016-0266-3.

[14]

李敏, 李绪清, 颜士杰, 等. ¹⁸F-脱氧葡萄糖PET/CT联合CA125在诊断卵巢癌复发转移中的应用价值[J].重庆医科大学学报, 2017, 42 (12):1635-1638. DOI:10.13406/j.cnki.cyxb.001417.
Li M, Li XQ, Yan SJ, et al. The value of ¹⁸F-FDG PET/CT combined with CA125 in the diagnosis of ovarian cancer recurrence and metastasis[J]. J Chongqing Med Univ, 2017, 42 (12):1635-1638. doi: 10.13406/j.cnki.cyxb.001417

[15]

Evangelista L, Palma MD, Gregianin M, et al. Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients[J]. J Turk Ger Gynecol Assoc, 2015, 16 (3):137-144. DOI:10.5152/jtgga.2015.15251.

[16]

廖胜斌, 李力, 阳志军.影像学检查对卵巢上皮性癌治疗后复发诊断价值的Meta分析[J].中国癌症防治杂志, 2016, 8 (2):113-119. DOI:10.3969/j.issn.1674-5671.2016.02.10.
Liao SB, Li L, Yang ZJ. Diagnostic value of imaging techniques for detecting epithelial ovarian cancer recurrence:a Meta analysis[J]. Chin J Oncol Prev and Treat, 2016, 8 (2):113-119. doi: 10.3969/j.issn.1674-5671.2016.02.10

[17]

李鹏, 赵卫威, 杨建伟. ¹⁸F-FDG PET-CT在探测卵巢癌术后复发与转移中的应用价值[J].国际放射医学核医学杂志, 2012, 36 (6):348-351. DOI:10.3760/cma.j.issn.1673-4114.2012.06.007.
Li P, Zhao WW, Yang JW. ¹⁸F-FDG PET-CT imaging in the detection of recurrent and metastasis ovarian cancer[J]. Int J Radiat Med Nucl Med, 2012, 36 (6):348-351. doi: 10.3760/cma.j.issn.1673-4114.2012.06.007

[18]

智生芳, 毕伟, 黄晓红, 等. ¹⁸F-FDG PET/CT对卵巢癌患者术后复发、转移的诊断敏感性及准确性研究[J].中国CT和MRI杂志, 2016, 14 (2):100-102. DOI:10.3969/j.issn.1672-5131. 2016. 02. 032.
Zhi SF, Bi W, Huang XH, et al. ¹⁸F-FDG PET/CT for the diagnosis sensitivity and accuracy of postoperative recurrence and metastasis in patients with ovarian cancer[J]. Chin J CT and MRI, 2016, 14 (2):100-102. doi: 10.3969/j.issn.1672-5131.2016.02.032

[19]

Dragosavac S, Derchain S, Caserta NM, et al. Staging recurrent ovarian cancer with ¹⁸FDG PET/CT[J]. Oncol Lett, 2013, 5 (2):593-597. DOI:10.3892/ol.2012.1075.

[20]

Musto A, Grassetto G, Marzola MC, et al. Management of epithelial ovarian cancer from diagnosis to restaging:an overview of the role of imaging techniques with particular regard to the contribution of ¹⁸F-FDG PET/CT[J]. Nucl Med Commun, 2014, 35 (6):588-597. DOI:10.1097/MNM.0000000000000091.

[21]

Vergote I, Amant F, Kristensen G, et al. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer[J]. Eur J Cancer, 2011, 47 Suppl 3:S88-92. DOI:10.1016/S0959-8049 (11)70152-6.

[22]

Nakamura K, Hongo A, Kodama J, et al. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer[J]. Acta Med Okayama, 2012, 66 (1):53-60. DOI:10.18926/AMO/48081.

[23]

Lee JW, Cho A, Lee JH, et al. The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer[J]. Eur J Nucl Med Mol Imaging, 2014, 41 (10):1898-1906. DOI:10.1007/s00259-014-2803-x.

[24]

Liao S, Lan X, Cao G, et al. Prognostic predictive value of total lesion glycolysis from ¹⁸F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer[J]. Clin Nucl Med, 2013, 38 (9):715-720. DOI:10.1097/RLU.0b013e31829f57fa.

[25]

Nie J, Zhang J, Gao J, et al. Diagnostic role of ¹⁸F-FDG PET/MRI in patients with gynecological malignancies of the pelvis: A systematic review and meta-analysis[J/OL]. PLoS One, 2017, 12 (5): e0175401[2018-01-16]. https://www.sciencedirect.com/science/article/pii/S0720048X15300838?via%3Dihub. DOI: 10.1371/journal.pone.0175401.

[26]

Grueneisen J, Schaarschmidt BM, Heubner M, et al. Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies:A comparison to PET/CT[J]. Eur J Radiol, 2015, 84 (11):2097-2102. DOI:10.1016/j.ejrad.2015. 08. 010.

[27]

Kitajima K, Suenaga Y, Ueno Y, et al. Value of fusion of PET and MRI in the detection of intra-pelvic recurrence of gynecological tumor:comparison with ¹⁸F-FDG contrast-enhanced PET/CT and pelvic MRI[J]. Ann Nucl Med, 2014, 28 (1):25-32. DOI:10.1007/s12149-013-0777-6.

[28]

Queiroz MA, Kubik-Huch RA, Hauser N, et al. PET/MRI and PET/CT in advanced gynaecological tumours:initial experience and comparison[J]. Eur Radiol, 2015, 25 (8):2222-2230. DOI:10.1007/s00330-015-3657-8.

[29]

Sawicki LM, Kirchner J, Grueneisen J, et al. Comparison of ¹⁸F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer:a follow-up study[J]. Eur J Nucl Med Mol Imaging, 2018, 45 (4):622-629. DOI:10.1007/s00259-017-3881-3.

[30]

李绍东, 高晶晶, 胡春峰, 等. PET/MRI融合图像诊断妇科恶性肿瘤盆腔复发[J].中国医学影像技术, 2016, 32 (10):1555-1559.DOI:10.13929/j.1003-3289.2016.10.022.
Li SD, Gao JJ, Hu CF, et al. PET/MRI fusion imaging diagnosis of gynecological malignant tumor pelvic recurrence[J]. Chin J Med Imaging Tech, 2016, 32 (10):1555-1559. doi: 10.13929/j.1003-3289.2016.10.022

[31]

Beiderwellen K, Grueneisen J, Ruhlmann V, et al.[¹⁸F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis:initial results[J]. Eur J Nucl Med Mol Imaging, 2015, 42 (1):56-65. DOI:10.1007/s00259-014-2902-8.

[32]

Bagade S, Fowler KJ, Schwarz JK, et al. PET/MRI Evaluation of Gynecologic Malignancies and Prostate Cancer[J]. Semin Nucl Med, 2015, 45 (4):293-303. DOI:10.1053/j.semnuclmed.2015.03.005.

[33]

Partovi S, Kohan A, Rubbert C, et al. Clinical oncologic applications of PET/MRI:a new horizon[J]. Am J Nucl Med Mol Imaging, 2014, 4 (2):202-212.

[34]

Kitajima K, Murakami K, Sakamoto S, et al. Present and future of FDG-PET/CT in ovarian cancer[J]. Ann Nucl Med, 2011, 25 (3):155-164. DOI:10.1007/s12149-010-0449-8.

[35]

Xin J, Ma Q, Guo Q, et al. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer[J]. Eur J Radio, 2016, 85 (4):751-759. DOI:10.1016/j.ejrad.2016.01.010.

[36]

Ehman EC, Johnson GB, Villanueva-Meyer JE, et al. PET/MRI:Where Might It Replace PET/CT?[J]. J Magn Reson Imaging, 2017, 46 (5):1247-1262. DOI:10.1002/jmri.25711.